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COnclusiOnS: Even though frequently focal, PBR is associated with a high incidence of 
recurrence, as well as a significant likelihood of late occlusion. Future investigations 
should address strategies to manage this condition. Serum Levels of High-Sensitive C-Reactive Protein 
Predict Restenosis After Stent Implantation in Patients 
With Unstable Angina 
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Background: It has been suggested that a systemic marker such as C-reactive protein 
(CRP) is higher in patients wth unstable angina pectoris (UAP) than in those with stable 
angina petioris. Persistent elevation of CRP in patients with UAP is predictive of future 
myocardial ischemia and infarction. However, an association between the serum levels 
of CRP and restenosis after coronary stent implantation in patients with UAP has not 
been fully elucidated. Therefore, this study was designed to determine whether CRP cor- 
relates with in-stent restenosis in patients with UAP. Methods: The study group consisted 
of 59 patients with UAP (mean age 65.2 * 10.7 years, Braunwald type IB; n = 29, type IlB 
or 1118; n = 30) who underwent successful coronary artery stenting (total: 73 coronary 
lesions). Patients with known inflammatory disease, heart failure, acute myocardial inf- 
arction, and chronic renal failure were excluded. Serum samples obtained from patients 
were immediately analyzed for high sensitive (hs-) CRP concentration, which was deter- 
mined by the latex enhanced immunoassay. This assay has a detection limit of 2 pg /dl. 
A successful stenting was defined as a residual diameter stenosis of 50% of the lumen 
diameter as measured by quantitative computerized angiography at 6.month follow-up. 
Results: The hs-CRP serum levels were significantly higher in cases with restenosis (n = 
20) than I” those without restenosis (n = 53) (211.7 * 43.7 vs. 114.5 * 13.2 pg /dl. p = 
0.006). Preprocedural minimal lumen diameter was significantly lower in restenotic group 
than in group without restenosis (0.45 f 0.08 vs. 0.67 * 0.06 mm, p = 0.049). The inci- 
dence of restenosis was significantly higher in cases with hs-CRP levels > 165 pg /dl 
Background: Patients treated with intracoronary radiation therapy (IRT) for in-stent rest- 
enosis (ISR) have recurrences and require repeat revascularization to the previuosly irra- 
diated site. This study examined the safety and effectiveness of repeat radiation. 
Methods: 69 patients with ISR who had recurrence of stenosis at a previously irradiated 
segment and were assigned for revascularization were treated with repeat IRT utilizing 
gamma lrlg2 (n=26) with a prescribed dose of 15 Gy at 2 mm or beta (n=43) with either 
P3’ dose of 20 Gy at 1 .O mm beyond the balloon sudace or Sri’@’ with a dose of 16 or 
23Gy at 2 mm. The antiplatelet regimen was twelve months of clopidogrel. 
Results: The mean age was 64 + 11 years, 62.3% were males, 41.2% diabetics and 
58.2% pts had previous CABG. Sixty one ISR lesions were in native coronary arteries, 5 
in saphenous vein grafts and 2 in left internal mammary graft. The mean time interval 
between the two radiation treatments was 14.6 f 9.1 months and the mean number of 
previous interventions to the target lesion was 3.9 + 2.1. The radiation was delivered suc- 
cessfully in all patients with no procedural or hospital complications. At present 6 months 
clinical follow-up is available for 30 pts. (Table) No differences in events behveen beta or 
gamma were seen in patients that underwent repeat IRT to the same site. 
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than in those with hs-CRP levels < 165 pg /dl(47.4% vs. 20.4%. p = 0.028). On multivari- Source 
ate analysis, the preprocedural CRP level (> 165 pg /dl) was the only independent pre- 0 0 0 
dictor of restenosis (relative risk [RR] = 2.22, p = 0.03). The clinical and demographic Death % 
characteristics of the population were similar for the two groups at baseline. Conclusion: 0 
Our results suggested that serum levels of hs-CRP predict restenosis after stent implan- 
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1099 Brachytherapy and Management of In- 
Stent Restenosis Conclusions: Repeat radiation to the same site using either beta or gamma radiation for 
refractory ISR and failed IRT is safe and effective at 6 months. 
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Background: Brachytherapy (BT) has been shown to reduce restenosis after coronary 
intervention. Little is known however regarding recurrence after BT restenosis. Because 
restenosis after BT is frequently at the irradiated edge, and therefore often focal, it is pos- 
sible the recurrent restenosis rate is low. This study evaluated the clinical outcomes after 
treatment for post-brachytherapy restenosis (PBR). 
Methods: 79 consecutive lesions of PBR were found over the past 3 years. Patients with 
clinical stent thrombosis (occlusions presenting as myocardial infarctions) were 
excluded. BT and PBR films were analyzed side by side. Patients were followed for 
recurrent events (TVR) after the PBR was treated with coronary intervention (PCI). 
Findings: BT had been used for in-stent restenosis (62%) as well as de nova lesions. 
The PBR was focal (~10 mm) in 67% of lesions, attributable to geographic miss in 63% 
with edge restenosis in 66%. Seventy-two lesions with PBR were treated with an addi- 
tional PCI, with one failure. Two others were treated with bypass surgery. Clinical follow- 
up was achieved in 91%, (median of 6 months, range l-33). Total occlusions were seen 
in 16%, possibly due to late stent thrombosis. Incidence of recurrent restenosis, and for 
specific subsets, are shown in the Table. 
Recurrent Restenosis Rate 
Background: Diffuse in-stent restenosls (ISR) is still a challenging problem and optimal 
treatment has not been established. 
Method: To compare the efficacy and safety of cutting balloon angioprasty (CB) versus 
Rotational Atherectomy with adjunctive balloon angioplasty (Rota), for the treatment of 
ISR, we studied 662 patients (1046 lesions) with a first ISR. 432 patients (512 lesions) 
received Rota and 450 patients (534 lesions) received CB. Basic characteristics in both 
groups are similar. 
Results: See table for immediate and long-term clinical outcomes between CB and 
Rota. 
Conclusions: These data shows that Rotational Atherectomy with adjunctive balloon 
angioplasty seems to offer a better long-term clinical outcome than cutting balloon angio- 
plasty. Randomized trial is needed. 
Characteristic 
Overall 45% 
Focal PBR 49% 
Edge restenosis 47% 
Geographic miss 45% 
Total occlusion PBR 29% 
BT done for in-stent restenosis 44% 
Gamma radiation 50% 
Beta radiation 45% 
